

Carlo Alessandria

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/223976/publications.pdf>

Version: 2024-02-01

23
papers

4,045
citations

516710

16
h-index

642732

23
g-index

23
all docs

23
docs citations

23
times ranked

3724
citing authors

#	ARTICLE	IF	CITATIONS
1	Acute-on-Chronic Liver Failure Is a Distinct Syndrome That Develops in Patients With Acute Decompensation of Cirrhosis. <i>Gastroenterology</i> , 2013, 144, 1426-1437.e9.	1.3	2,211
2	Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. <i>Lancet, The</i> , 2018, 391, 2417-2429.	13.7	345
3	Epidemiology and Effects of Bacterial Infections in Patients With Cirrhosis Worldwide. <i>Gastroenterology</i> , 2019, 156, 1368-1380.e10.	1.3	296
4	The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. <i>Journal of Hepatology</i> , 2020, 73, 842-854.	3.7	282
5	Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF. <i>Journal of Hepatology</i> , 2020, 72, 688-701.	3.7	223
6	Terlipressin and albumin for type-1 hepatorenal syndrome associated with sepsis. <i>Journal of Hepatology</i> , 2014, 60, 955-961.	3.7	100
7	Efficacy of Albumin Treatment for Patients with Cirrhosis and Infections Unrelated to Spontaneous Bacterial Peritonitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 963-973.e14.	4.4	77
8	Clinical features and evolution of bacterial infection-related acute-on-chronic liver failure. <i>Journal of Hepatology</i> , 2021, 74, 330-339.	3.7	76
9	Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 31-41.	8.1	75
10	The Use of Rifaximin in Patients With Cirrhosis. <i>Hepatology</i> , 2021, 74, 1660-1673.	7.3	67
11	HDL-related biomarkers are robust predictors of survival in patients with chronic liver failure. <i>Journal of Hepatology</i> , 2020, 73, 113-120.	3.7	58
12	Prevention of paracentesis-induced circulatory dysfunction in cirrhosis: Standard vs half albumin doses. A prospective, randomized, unblinded pilot study. <i>Digestive and Liver Disease</i> , 2011, 43, 881-6.	0.9	54
13	On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites. <i>Journal of Hepatology</i> , 2021, 74, 340-349.	3.7	38
14	Dietary approach and gut microbiota modulation for chronic hepatic encephalopathy in cirrhosis. <i>World Journal of Hepatology</i> , 2019, 11, 489-512.	2.0	34
15	Transition to decompensation and acute-on-chronic liver failure: Role of predisposing factors and precipitating events. <i>Journal of Hepatology</i> , 2021, 75, S36-S48.	3.7	29
16	The role of microbiota in autism spectrum disorders. <i>Minerva Gastroenterologica E Dietologica</i> , 2018, 64, 333-350.	2.2	27
17	Endpoints and design of clinical trials in patients with decompensated cirrhosis: Position paper of the LiverHope Consortium. <i>Journal of Hepatology</i> , 2021, 74, 200-219.	3.7	16
18	Transjugular intrahepatic porto-systemic shunt in cirrhotic patients with hepatorenal syndrome - chronic kidney disease: Impact on renal function. <i>Digestive and Liver Disease</i> , 2022, 54, 1101-1108.	0.9	12

#	ARTICLE	IF	CITATIONS
19	Adrenal function and microbial DNA in noninfected cirrhotic patients with ascites: Relationship and effect on survival. <i>Digestive and Liver Disease</i> , 2015, 47, 702-708.	0.9	7
20	Position paper on liver and kidney diseases from the Italian Association for the Study of Liver (AISF), in collaboration with the Italian Society of Nephrology (SIN). <i>Digestive and Liver Disease</i> , 2021, 53, S49-S86.	0.9	7
21	Assessment of glomerular filtration rate in patients with cirrhosis: Available tools and perspectives. <i>Liver International</i> , 2022, , .	3.9	5
22	Treatment With Simvastatin and Rifaximin Restores the Plasma Metabolomic Profile in Patients With Decompensated Cirrhosis. <i>Hepatology Communications</i> , 2022, 6, 1100-1112.	4.3	5
23	Liver involvement in adult-onset Still's disease: our experience in a third level liver unit and review of the literature. <i>Minerva Gastroenterology</i> , 2024, 69, .	0.5	1